Track all markets on TradingView
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Media

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

  • November 4, 2024
  • 8 Views

Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG’s Treg-focused action as a potential breakthrough for Alopecia areata treatment.

Latest Ratings for NKTR

Date Firm Action From To
Mar 2022 Oppenheimer Upgrades Perform Outperform
Nov 2021 Benchmark Upgrades Hold Buy
Nov 2021 SVB Leerink Maintains Market Perform

View More Analyst Ratings for NKTR

View the Latest Analyst Ratings

read more

​ 

Share This Post:

Leave a Reply

Your email address will not be published. Required fields are marked *

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.